Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 3/2011

01.06.2011

Alternative and Complementary Treatments for Metabolic Syndrome

verfasst von: Mariya Power, Richard Pratley

Erschienen in: Current Diabetes Reports | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Metabolic syndrome is defined by a cluster of cardiovascular disease risk factors that are associated with insulin resistance. In recent years, a number of innovative nutritional strategies have been proposed as safe alternative treatments to reduce the morbidity as well as the cost of treating metabolic syndrome. Of these, dietary supplementation with chromium picolinate or cinnamon extract has been studied most extensively. These interventions may attenuate insulin resistance and reduce the cardiovascular risk factors that together comprise the metabolic syndrome. However, more clinical trials are needed to determine the dose and duration of such treatments to make specific recommendations for populations with metabolic syndrome.
Literatur
1.
2.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486–2497.
3.
Jeejeebhoy KN, Chu RC, Marliss EB, et al. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr. 1977;30:531–8.PubMed
4.
Via M, Scurlock C, Raikhelkar J, et al. Chromium infusion reverses extreme insulin resistance in a cardiothoracic ICU patient. Nutr Clin Pract. 2008;23:325–8.PubMedCrossRef
5.
Anderson RA. Chromium and parenteral nutrition. Nutrition. 1995;11:83–6.PubMed
6.
Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr. 1997;16:404–10.PubMed
7.
Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr. 1998;17:548–55.PubMed
8.
National Research Counsil, Food and Nutrition Board. Recommended dietary allowances. 10th ed. Washington: National Academy Press; 1989.
9.
Anderson RA, Polansky MM, Bryden NA, et al. Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. J Nutr. 1983;113:276–81.PubMed
10.
Bunker VW, Lawson MS, Delves HT, Clayton BE. The uptake and excretion of chromium by the elderly. Am J Clin Nutr. 1984;39:797–802.PubMed
11.
Anderson RA, Kozlovsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr. 1985;41:1177–83.PubMed
12.
Offenbacher EG. Promotion of chromium absorptionby ascorbic acid. Trace Elem Electrolytes. 1994;11:178.
13.
Lim TH, Sargent 3rd T. Kusubov N: Kinetics of trace element chromium(III) in the human body. Am J Physiol. 1983;244:R445–54.PubMed
14.
Schwarz K, Mertz W. Chromium(III) and the glucose tolerance factor. Arch Biochem Biophys. 1959;85:292–5.PubMedCrossRef
15.
Vincent JB. Elucidating a biological role for chromium at a molecular level. Acc Chem Res. 2000;33:503–10.PubMedCrossRef
16.
Hummel M, Standl E, Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res. 2007;39:743–51.PubMedCrossRef
17.
Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diab Care. 2004;27:2741–51.CrossRef
18.
Cefalu WT, Wang ZQ, Zhang XH, et al. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr. 2002;132:1107–14.PubMed
19.
Sherman L, Glennon JA, Brech WJ, et al. Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. Metabolism. 1968;17:439–42.PubMedCrossRef
20.
Rabinowitz MB, Gonick HC, Levin SR, Davidson MB. Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. Diab Care. 1983;6:319–27.CrossRef
21.
Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diab Care. 1994;17:1449–52.CrossRef
22.
Thomas VL, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors. Biol Trace Elem Res. 1996;55:297–305.PubMedCrossRef
23.
Trow LG, Lewis J, Greenwood RH, et al. Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes. Int J Vitam Nutr Res. 2000;70:14–8.PubMedCrossRef
24.
Gunton JE, Cheung NW, Hitchman R, et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diab Care. 2005;28:712–3.CrossRef
25.
Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997;46:1786–91.PubMedCrossRef
26.
Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, et al. Effect of chromium picolinate on insulin sensitivity in vivo. J Trace Elem Exp Med. 1999;12:71–83.CrossRef
27.
Iqbal N, Cardillo S, Volger S, et al.: Chromium Picolinate Does Not Improve Key Features of Metabolic Syndrome in Obese Nondiabetic Adults. Metab Syndr Relat Disord 2009.
28.
Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr. 1996;63:954–65.PubMed
29.
Grant KE, Chandler RM, Castle AL, Ivy JL. Chromium and exercise training: effect on obese women. Med Sci Sports Exerc. 1997;29:992–8.PubMed
30.
Martin J, Wang ZQ, Zhang XH, et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diab Care. 2006;29:1826–32.CrossRef
31.
Proctor SD, Kelly SE, Stanhope KL, et al. Synergistic effects of conjugated linoleic acid and chromium picolinate improve vascular function and renal pathophysiology in the insulin-resistant JCR:LA-cp rat. Diab Obes Metab. 2007;9:87–95.CrossRef
32.
Roeback Jr JR, Hla KM, Chambless LE, Fletcher RH. Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers. A randomized, controlled trial. Ann Intern Med. 1991;115:917–24.PubMed
33.
Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. Metabolism. 1992;41:768–71.PubMedCrossRef
34.
Padmavathi IJ, Rao KR, Venu L, et al. Chronic maternal dietary chromium restriction modulates visceral adiposity: probable underlying mechanisms. Diabetes. 2010;59:98–104.PubMedCrossRef
35.
Dugoua JJ, Seely D, Perri D, et al. From type 2 diabetes to antioxidant activity: a systematic review of the safety and efficacy of common and cassia cinnamon bark. Can J Physiol Pharmacol. 2007;85:837–47.PubMedCrossRef
36.
Anderson RA, Broadhurst CL, Polansky MM, et al. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem. 2004;52:65–70.PubMedCrossRef
37.
Imparl-Radosevich J, Deas S, Polansky MM, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm Res. 1998;50:177–82.PubMedCrossRef
38.
Qin B, Nagasaki M, Ren M, et al. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diab Res Clin Pract. 2003;62:139–48.CrossRef
39.
Qin B, Nagasaki M, Ren M, et al. Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Horm Metab Res. 2004;36:119–25.PubMedCrossRef
40.
Sheng X, Zhang Y, Gong Z, et al. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Res. 2008;2008:581348.PubMed
41.
Khan A, Safdar M, Ali Khan MM, et al. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diab Care. 2003;26:3215–8.CrossRef
42.
Vanschoonbeek K, Thomassen BJ, Senden JM, et al. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr. 2006;136:977–80.PubMed
43.
• Crawford P: Effectiveness of cinnamon for lowering hemoglobin A1C in patients with type 2 diabetes: a randomized, controlled trial. J Am Board Fam Med 2009, 22:507–512. This is a recent clinical trial demonstrating positive effect of cinnamon extract on HbA 1c levels in people with type 2 diabetes.PubMedCrossRef
44.
Ziegenfuss TN, Hofheins JE, Mendel RW, et al. Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. J Int Soc Sports Nutr. 2006;3:45–53.PubMedCrossRef
45.
Feiner JJ, McNurlan MA, Ferris RE, et al. Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study. Diab Obes Metab. 2008;10:151–8.
46.
Wang JG, Anderson RA, Graham 3rd GM, et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007;88:240–3.PubMedCrossRef
47.
Solomon TP, Blannin AK. Effects of short-term cinnamon ingestion on in vivo glucose tolerance. Diab Obes Metab. 2007;9:895–901.CrossRef
Metadaten
Titel
Alternative and Complementary Treatments for Metabolic Syndrome
verfasst von
Mariya Power
Richard Pratley
Publikationsdatum
01.06.2011
Verlag
Current Science Inc.
Erschienen in
Current Diabetes Reports / Ausgabe 3/2011
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-011-0184-0

Weitere Artikel der Ausgabe 3/2011

Current Diabetes Reports 3/2011 Zur Ausgabe

ReviewPaper

Gut Microbiota and the Pathogenesis of Insulin Resistance

ReviewPaper

Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes

ReviewPaper

Cardiovascular Function/Dysfunction in Adolescents with Type 1 Diabetes

ReviewPaper

Human Vascular Endothelial Cells: A Model System for Studying Vascular Inflammation in Diabetes and Atherosclerosis

ReviewPaper

Adipose Tissue Dysfunction in Polycystic Ovary Syndrome

ReviewPaper

Adipose Tissue Vascularization: Its Role in Chronic Inflammation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise